183 related articles for article (PubMed ID: 31571408)
1. Reduced-volume tumor-bed boost is not associated with inferior local control and survival outcomes in high-risk medulloblastoma.
Tian S; Sudmeier LJ; Zhang C; Madden NA; Buchwald ZS; Shu HG; Curran WJ; Eaton BR; Esiashvili N
Pediatr Blood Cancer; 2020 Jan; 67(1):e28027. PubMed ID: 31571408
[TBL] [Abstract][Full Text] [Related]
2. Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa?
Fukunaga-Johnson N; Lee JH; Sandler HM; Robertson P; McNeil E; Goldwein JW
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):143-6. PubMed ID: 9747831
[TBL] [Abstract][Full Text] [Related]
3. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
[TBL] [Abstract][Full Text] [Related]
4. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma.
Moxon-Emre I; Bouffet E; Taylor MD; Laperriere N; Scantlebury N; Law N; Spiegler BJ; Malkin D; Janzen L; Mabbott D
J Clin Oncol; 2014 Jun; 32(17):1760-8. PubMed ID: 24516024
[TBL] [Abstract][Full Text] [Related]
5. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
6. Vulnerability of white matter to insult during childhood: evidence from patients treated for medulloblastoma.
Moxon-Emre I; Bouffet E; Taylor MD; Laperriere N; Sharpe MB; Laughlin S; Bartels U; Scantlebury N; Law N; Malkin D; Skocic J; Richard L; Mabbott DJ
J Neurosurg Pediatr; 2016 Jul; 18(1):29-40. PubMed ID: 27015518
[TBL] [Abstract][Full Text] [Related]
7. Prolongation of radiotherapy duration is associated with inferior overall survival in patients with pediatric medulloblastoma and central nervous system primitive neuroectodermal tumors.
Baliga S; Bajaj BVM; Kabarriti R; Grassberger C; Patteson B; Yeap B; Fox JL; Garg MK; Yock TI
Pediatr Blood Cancer; 2020 Oct; 67(10):e28558. PubMed ID: 32710698
[TBL] [Abstract][Full Text] [Related]
8. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival.
Eaton BR; Esiashvili N; Kim S; Weyman EA; Thornton LT; Mazewski C; MacDonald T; Ebb D; MacDonald SM; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):133-138. PubMed ID: 26700707
[TBL] [Abstract][Full Text] [Related]
10. Local control in non-metastatic medulloblastoma.
Christopherson KM; Bradley JA; Rotondo RL; Pincus DW; Fort JA; Morris CG; Mendenhall NP; Marcus RB; Indelicato DJ
Acta Oncol; 2014 Sep; 53(9):1151-7. PubMed ID: 24991891
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy and overall survival in adult medulloblastoma.
Kann BH; Lester-Coll NH; Park HS; Yeboa DN; Kelly JR; Baehring JM; Becker KP; Yu JB; Bindra RS; Roberts KB
Neuro Oncol; 2017 Feb; 19(2):259-269. PubMed ID: 27540083
[TBL] [Abstract][Full Text] [Related]
12. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients.
Massimino M; Sunyach MP; Barretta F; Gandola L; Garegnani A; Pecori E; Spreafico F; Bonneville-Levard A; Meyronet D; Mottolese C; Boschetti L; Biassoni V; Schiavello E; Giussani C; Carrabba G; Diletto B; Pallotti F; Stefini R; Ferrari A; Terenziani M; Casanova M; Luksch R; Meazza C; Podda M; Chiaravalli S; Puma N; Bergamaschi L; Morosi C; Calareso G; Giangaspero F; Antonelli M; Buttarelli FR; Frappaz D
J Neurooncol; 2020 Jul; 148(3):619-628. PubMed ID: 32567042
[TBL] [Abstract][Full Text] [Related]
13. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.
Yock TI; Yeap BY; Ebb DH; Weyman E; Eaton BR; Sherry NA; Jones RM; MacDonald SM; Pulsifer MB; Lavally B; Abrams AN; Huang MS; Marcus KJ; Tarbell NJ
Lancet Oncol; 2016 Mar; 17(3):287-298. PubMed ID: 26830377
[TBL] [Abstract][Full Text] [Related]
14. Late toxicity following craniospinal radiation for early-stage medulloblastoma.
Christopherson KM; Rotondo RL; Bradley JA; Pincus DW; Wynn TT; Fort JA; Morris CG; Mendenhall NP; Marcus RB; Indelicato DJ
Acta Oncol; 2014 Apr; 53(4):471-80. PubMed ID: 24564687
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.
Gupta T; Maitre M; Sastri GJ; Krishnatry R; Shirsat N; Epari S; Sahay A; Chinnaswamy G; Patil V; Shetty P; Moiyadi A
J Neurooncol; 2019 Sep; 144(2):283-291. PubMed ID: 31236820
[TBL] [Abstract][Full Text] [Related]
16. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
Lee JW; Lim DH; Sung KW; Cho HW; Ju HY; Hyun JK; Yoo KH; Koo HH; Suh YL; Joung YS; Shin HJ
Cancer Med; 2020 Aug; 9(16):5807-5818. PubMed ID: 32608158
[TBL] [Abstract][Full Text] [Related]
17. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation.
Saran FH; Driever PH; Thilmann C; Mose S; Wilson P; Sharpe G; Adamietz IA; Böttcher HD
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):959-67. PubMed ID: 9869216
[TBL] [Abstract][Full Text] [Related]
18. Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy?
Burcu A; Nazan Ç; Özgür Ö; Serra K; Mehmet K; Serap A; Bengü D; Canan V; Haldun Ö; Savaş K; Tuncer T; Taner A; Yeşim E; Ömer K; Yavuz A
Childs Nerv Syst; 2018 Sep; 34(9):1657-1662. PubMed ID: 29868932
[TBL] [Abstract][Full Text] [Related]
19. Quality control of low dose craniospinal irradiation for low risk medulloblastoma.
Benk V; Bouhnik H; Raquin MA; Kalifa C; Habrand JL
Br J Radiol; 1995 Sep; 68(813):1009-13. PubMed ID: 7496681
[TBL] [Abstract][Full Text] [Related]
20. Medulloblastoma--prognostic factors and outcome of treatment: review of the Mayo Clinic experience.
Garton GR; Schomberg PJ; Scheithauer BW; Shaw EG; Ilstrup DM; Blackwell CR; Laws ER; Earle JD
Mayo Clin Proc; 1990 Aug; 65(8):1077-86. PubMed ID: 2117687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
